Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy in multiple sclerosis.

Mark J Tullman1, Fred D Lublin

  • 1The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY 10029, USA. Mark.Tullman@mssm.edu

Current Neurology and Neuroscience Reports
|May 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognition in multiple sclerosis within the modern diagnostic and treatment era.

Brain : a journal of neurology·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Annals of neurology·2025
Same author

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.

Neurology·2025
Same author

Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis.

Annals of clinical and translational neurology·2024
Same author

Worsening MS-A reappraisal of how we characterize the MS disease course.

Multiple sclerosis (Houndmills, Basingstoke, England)·2023

Combining therapies for multiple sclerosis (MS) is appealing due to modest drug benefits. However, careful study is needed to ensure safety and efficacy, as drug interactions are a concern.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is now a treatable neurologic condition.
  • Current disease-modifying therapies offer modest benefits.
  • Challenges exist in conducting clinical trials for MS treatments.

Purpose of the Study:

  • To explore the rationale for combining therapies in multiple sclerosis.
  • To highlight the need for careful selection of agents in combination therapy.
  • To emphasize the necessity of rigorously controlled studies for MS treatment.

Main Methods:

  • Review of current therapeutic strategies in multiple sclerosis.
  • Analysis of challenges in MS clinical trial design.
  • Consideration of immunomodulatory drug interactions and adverse effects.

Related Experiment Videos

Main Results:

  • Combination therapy in MS presents a logical approach due to limited individual agent efficacy.
  • Potential for drug interactions and unforeseen adverse effects necessitates caution.
  • Lack of definitive data on combination therapy safety and efficacy.

Conclusions:

  • Further rigorously controlled studies are essential.
  • Determining the safest and most effective combination therapies for MS is critical.
  • Optimizing treatment strategies for multiple sclerosis requires ongoing research.